1. Scrip

AlloVir Gains Third RMAT Designation For Antiviral T Cell Therapy

Could Help Prevent Infection In 40,000 Patients

 
• By Andrew McConaghie

Gaining the special regulatory status in a prophylactic setting for posoleucel is the most significant yet for the T cell therapy developer.

Cell Separator
A cell separator collects stem cells for use in an allogenic hematopoietic stem cell transplant. • Source: Alamy

Allovir has been lifted after posoleucel, its lead off-the-shelf (allogeneic) T-cell therapy to treat and prevent viral diseases, was awarded a third Regenerative Medicine Advanced Therapy (RMAT) designation to potentially speed up approval in the US.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.